| The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. | leukemia, |
| Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. | neoplasm, |
| Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia. | leukemia, |
| BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts. | leukemia, |
| MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. | leukemia, |
| Data indicate that the biosensor showed excellent analytical performance for the detection of the BCR/ABL oncogene in clinical samples of patients with leukemia. | leukemia, |
| bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. | leukemia, |
| bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia. | leukemia, |
| Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). | leukemia, |
| BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells. | leukemia, |
| Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture. | leukemia, |
| An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. | leukemia, |
| The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. | leukemia, |
| Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. | leukemia, |
| BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. | leukemia, |
| Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus. | thymoma, |
| Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. | leukemia, |
| A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. | None |
| Bcr: a negative regulator of the Bcr-Abl oncoprotein. | None |
| Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). | None |